AstraZeneca Drops 7% After Buzz of Merger Talks with Bristol Myers Squibb

Shares of AstraZeneca took a hit Monday, sliding almost 7% in London's market after reports surfaced about merger conversations with Bristol Myers Squibb. The potential deal would combine two pharmaceutical giants into an entity with an eye-popping valuation close to $400 billion.

AstraZeneca's price dropped to roughly 11,800 pence, while the FTSE 100 barely budged. Meanwhile, Bristol Myers Squibb shares ticked upward in pre-market U.S. trading, edging higher after closing near their annual peak last week.

The combined company would rank among the industry's behemoths, with AstraZeneca's market capitalization around $264 billion and Bristol Myers at about $133 billion. The Financial Times cited unnamed insiders who mentioned these talks happening over the last few months, but stressed they could falter or stall, with no details officially confirmed or shared so far.

Both firms have posted solid quarterly results recently. AstraZeneca beat EPS estimates with $2.63 and narrowly missed revenue projections with $15.38 billion in Q2. Bristol Myers surpassed expectations more comfortably, reporting Q2 EPS of $2.04 against a $1.61 consensus and revenues topping $12.9 billion.

AstraZeneca's leadership, helmed by Pascal Soriot, has turned down takeover bids before, notably rebuffing Pfizer's $118 billion offer back in 2014, and its shares have surged multiple folds since that rejection. The firm also committed billions to U.S. manufacturing and R&D expansions and floated plans for a direct listing stateside, aiming to tap into heftier valuations on American exchanges. It's unclear how a merger would align with these ambitions.

For its part, Bristol Myers has leaned on acquisitions as a strategy to offset patent cliffs and invigorate its drug pipeline. Their oncology and immunology portfolios, bolstered by partnerships with companies like BioNTech, have helped fuel recent stock gains. Yet merging with AstraZeneca could boost diversification and scale even further.

Investors are eyeing earnings reports slated for late October from both companies that could shed more light on future prospects. Bristol Myers is up first on October 29, with street estimates forecasting EPS of $1.61 and revenue around $12 billion. AstraZeneca follows on October 30 with expected EPS near $2.63 and revenues topping $16 billion.

Some analysts expressed skepticism about the rationale behind the talks. Jefferies pointed out AstraZeneca's already robust growth trajectory and innovation engine that might not need a mega acquisition to sustain momentum. Antitrust scrutiny also looms large as both companies have significant overlapping oncology operations, creating regulatory hurdles ahead.

Meanwhile, the looming expiration of patents for some Bristol Myers drugs could weigh on the merged entity's long-term growth, even if short-term earnings might get a boost. The next few months promise to be telling for this potential combination.